Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Carcinoma, Hepatocellular 23Carcinoma, Non-Small-Cell Lung 12Colorectal Neoplasms 8Biliary Tract Neoplasms 6Squamous Cell Carcinoma of Head and Neck 5Mesothelioma, Malignant 5Melanoma 5Liver Neoplasms 5Cholangiocarcinoma 5Urinary Bladder Neoplasms 4Prostatic Neoplasms 4Neoplasms 4Diabetes Mellitus, Insulin-Dependent, 12 4Neoplasm Metastasis 3Lung Neoplasms 3Head and Neck Neoplasms 3Fallopian Tube Neoplasms 3Carcinoma, Renal Cell 3Breast Neoplasms 3Triple Negative Breast Neoplasms 2Stomach Neoplasms 2Recurrence 2Ovarian Neoplasms 2Neoplasms, Germ Cell and Embryonal 2Mesothelioma 2Gallbladder Neoplasms 2Endometrial Neoplasms 2Adenocarcinoma Of Esophagus 2Vascular Neoplasms 1Uveal Melanoma 1

Interventions

Ipilimumab 5Radiotherapy 4Nivolumab 4Doxorubicin 4CTLA-4 Antigen 4pembrolizumab 3Gemcitabine 3cabozantinib 2brostallicin 2Sunitinib 2Specimen Handling 2Radiation Dose Hypofractionation 2Radiation 2Magnetic Resonance Spectroscopy 2Ifosfamide 2Docetaxel 2Biopsy 23-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 2tremelimumab 1toripalimab 1talimogene laherparepvec 1spartalizumab 1soblidotin 1sintilimab 1saracatinib 1romidepsin 1reolysin 1perifosine 1pazopanib 1fludarabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Histiocytoma, Malignant Fibrous × tremelimumab × Clear all
NCT02815995 2025-06-12

Multi-Arm Study to Test the Efficacy of Immunotherapeutic Agents in Multiple Sarcoma Subtypes

M.D. Anderson Cancer Center

Phase 2 Completed
57 enrolled 18 charts
Sarcoma

Hemangiosarcoma, Leiomyosarcoma, Osteosarcoma, Sarcoma, Synovial, Hemangioendothelioma, Epithelioid, Vascular Neoplasms, Histiocytoma, Malignant Fibrous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡